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ABSTRACT
Purpose: To determine if topical beta-blocker use is associated with increased cardiovascular
mortality, particularly among people with self-reported glaucoma.
Methods: All participants who participated in the first health check (N = 25,639) of the European
Prospective Investigation into Cancer (EPIC) Norfolk cohort (1993–2013) were included in this
prospective cohort study, with a median follow-up of 17.0 years. We determined use of topical
beta-blockers at baseline through a self-reported questionnaire and prescription check at the first
clinical visit. Cardiovascular mortality was ascertained through data linkage with the Office for
National Statistics mortality database. Hazard ratios (HRs) were estimated using multivariable Cox
regression models. Meta-analysis of the present study’s results together with other identified
literature was performed using a random effects model.
Results: We did not find an association between the use of topical beta-blockers and cardiovas-
cular mortality (HR 0.93, 95% confidence interval, CI, 0.67–1.30). In the 514 participants with self-
reported glaucoma, no association was found between the use of topical beta-blockers and
cardiovascular mortality (HR 0.89, 95% CI 0.56–1.40). In the primary meta-analysis of four publica-
tions, there was no evidence of an association between the use of topical beta-blockers and
cardiovascular mortality (pooled HR estimate 1.10, 95% CI 0.84–1.36).
Conclusion: Topical beta-blockers do not appear to be associated with excess cardiovascular
mortality. This evidence does not indicate that a change in current practice is warranted, although
clinicians should continue to assess individual patients and their cardiovascular risk prior to
commencing topical beta-blockers.
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Introduction
Topical beta-blockers remain one of the primary
treatments for glaucoma.1 Previous studies have
described associations between long-term use of topi-
cal beta-blockers and increased cardiovascular
mortality.2,3 Topical medications can reach systemic
concentrations, and up to 80% of timolol has been
shown to be systemically absorbed.4 Furthermore,
long-term treatment with timolol has been associated
with dyslipidemia,5–7 also indicating systemic effects
from topical treatment. Additional cardiovascular
mechanisms include dysrhythmias and impaired car-
diac output,8 although investigations into the associa-
tion between topical beta-blocker use and
cardiovascular mortality show conflicting results.
The Blue Mountains Eye Study2 reported an increase
in cardiovascular mortality in glaucoma patients
using topical beta-blockers, whereas the Rotterdam
Study9 found non-significant associations with long-
term exposure. Given the significant global burden of
cardiovascular disease, the widespread use of topical
beta-blockers10 as a cost-effective treatment, and the
availability of off-patent effective alternatives in the
form of prostaglandin analogues,11 there is clear jus-
tification to explore the question further.
This study aimed to investigate the effects of topical
beta-blockers on cardiovascular mortality. First, we
examined the association in the European Prospective
Investigation into Cancer (EPIC) Norfolk Cohort
Study. Second, we conducted a systematic review of
the literature and pooled our results with previously
published data in a meta-analysis.
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Materials and methods
EPIC-Norfolk is a large, prospective, cohort study. All
participants were invited to attend via their general practi-
tioner (GP) betweenMarch 1993 and December 1997. The
participation rate was 33%. As nearly all residents in the
United Kingdom are registered with a GP through the
NationalHealth Service, general practice lists serve as popu-
lation registers. Detailed methods have been published
elsewhere.12 In brief, all persons aged 40–79 years in data-
bases of the 35 participating general practices in the region
were sent invitations (N = 77,360). Consent was received
from 30,445 participants, of which 25,639 attended the first
health examination.12 The Norfolk Local Research Ethics
Committee approved the EPIC-Norfolk study, and all
volunteers gave written informed consent.
We ascertained topical beta-blocker use through com-
pletion of a detailed health and lifestyle questionnaire and
by asking participants to bring all previous prescriptions
and medications they were taking at baseline to the health
examination, where prescriptions and medicines were
checked by trained nurses.12 All EPIC-Norfolk partici-
pants were followed up for mortality and flagged for
death certification at the Office for National Statistics,
with vital status ascertained on the whole cohort up
until 30 June 2013.12 Coding of death certificates was
performed by trained nosologists according to the
International Classification of Diseases (ICD).
Cardiovascular mortality was defined as any individual
with ICD codes 410–448 (ICD 9th revision) or ICD codes
I10–I79 (ICD 10th revision) listed as cause of death.
The design and characteristics of EPIC-Norfolk assess-
ment methods for all covariables of interest have been
described previously.12 The following covariables were
measured through a self-reported questionnaire: History
of angina, cholesterol, diabetes, education, glaucoma, myo-
cardial infarction, stroke, hypertension, smoking and social
class. Glaucoma ascertainment was also self-reported
through direct questioning on the questionnaire. Systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
were recorded during a health examination as the mean of
two measurements taken from the right arm with the
participant seated for 5 minutes, using an Accutorr Plus
blood pressure monitor (Mindray, Huntingdon, UK).
Differences in characteristics of participants by
exposure status were evaluated using Chi-squared and
Welch’s unpaired T-tests. All participants with missing
covariable data were included in the initial analyses,
with a complete case analysis conducted on the final
models. Associations between use of topical beta-block-
ers and cardiovascular mortality were assessed using
Cox proportional hazard models. All analyses were
adjusted for age and sex. Potential confounders were
selected using univariable comparisons of covariables,
and variables which were significantly associated with
both exposure and outcome were included. We also
included covariables based on a priori assumptions of
known confounders in the final Cox model. Raised
cholesterol was considered to be a potential mediator
on the causal pathway5–7 and therefore not included in
the final model. A subgroup analysis was performed to
look at the association between topical beta-blocker expo-
sure and cardiovascular mortality in only participants
with self-reported glaucoma. Multiple sensitivity analyses
were carried out to explore the robustness of our findings.
The effect of different covariables, glaucoma status, cho-
lesterol as a confounder rather than a mediator, whether
having manifest cardiovascular disease might alter expo-
sure patterns and introduce reverse causation were
explored. No adjustments were made for change in expo-
sure status over the course of the study period. This
allowed direct comparison with methods from the Blue
Mountains Eye Study2 and Rotterdam Study9. However,
as glaucoma is an age-related disease,13 and given the
older age range within the EPIC-Norfolk cohort,12 it is
probable that further incident cases of glaucoma and thus
topical beta-blocker exposure occurred. Therefore, we
used census-derived population data, together with epi-
demiological models to estimate the potential impact of
incident glaucoma during the follow-up period. We also
examined the association between topical beta-blocker
use and cardiovascular mortality at the second health
check (1998–2000) to explore the effect of changing treat-
ment during the follow-up period.
Systematic literature review
A literature-based meta-analysis was performed to look
for published evidence on the association between topi-
cal beta-blockers and cardiovascular mortality. The
search strategy was performed within PubMed
(National Center for Biotechnology Information, USA).
The following terms were used in the literature
search strategy in July 2014;
(1) topical[All Fields], (2) “adrenergic beta-antagonists”
[Pharmacological Action] OR “adrenergic beta-
antagonists”[MeSH Terms] OR (“adrenergic” [All Fields]
AND “beta-antagonists”[All Fields]) OR “adrenergic beta-
antagonists” [All Fields] OR (“beta” [All Fields] AND
“blockers” [All Fields]) OR “beta blockers”[All Fields], (3)
“glaucoma”[MeSH Terms] OR “glaucoma”[All Fields], (4)
“mortality”[Subheading] OR “mortality”[All Fields] OR
“mortality”[MeSH Terms], (5) (“cardiovascular
system”[MeSH Terms] OR (“cardiovascular”[All Fields]
AND “system”[All Fields]) OR “cardiovascular
system”[All Fields] OR “cardiovascular”[All Fields]) AND
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(“mortality”[Subheading] OR “mortality”[All Fields] OR
“mortality”[MeSH Terms]), (6), (1) AND (2), (7) (3) OR
(6), (8) (4) OR (5). The search (7) AND (8) returned 278
publications.
Publications were reviewed if they reported associa-
tions between topical beta-blocker use and cardiovas-
cular mortality. No exclusion criteria were applied to
language or journal publication date. Publications were
excluded if they were non-human studies, in-vitro
experiments, ecological studies, case series, case reports,
opinion pieces, letters, did not look at topical beta-
blockers as an exposure and did not look at cardiovas-
cular mortality as an outcome. Publications were addi-
tionally excluded if they were reviews of published
associations with no new contributing data.
The exclusion process is detailed in Figure 1. The
resulting three articles were all cohort studies and are
summarized in Table 1.
A random effects model was used to pool the results
and accommodate between-study heterogeneity.
Between-study heterogeneity was analyzed using the
I-squared test statistic. All analyses were carried out in
Stata 12.1 (StataCorp, College Station, TX, USA).
Results
A total of 25,639 participants with a mean age of 59.2 years
(standard deviation, SD, 9.32 years) were included in this
analysis. Participants were followed up for a median of 17.0
years and a total of 407,524 person-years. During the
follow-up period, 6525 individuals died (25.4%) of which
2158 deaths (33.1%) were attributed to cardiovascular dis-
ease. A total of 19,114 individuals were alive at the time of
follow-up. Topical beta-blockers were used by 179 indivi-
duals (0.7%) of whom 82 (45.8%) had died during follow-
up. Of these 36 (20.1%) participants who used topical beta-
blockers died of cardiovascular causes.
Table 2 details the baseline characteristics of the
cohort. Those using topical beta-blockers were older
at baseline, with a mean difference of 7.4 years (95%
confidence interval, CI, 6.2–8.5 years). Just over half
(57.8%) of participants using topical beta-blockers were
male. Significant differences in the proportions of those
with diabetes, angina, myocardial infarction, stroke,
self-reported hypertension, raised cholesterol, and
raised SBP at baseline were observed, with higher pro-
portions in those using topical beta-blockers. A signifi-
cantly higher proportion of ever smokers were also seen
in topical beta-blocker users. Non-significant differ-
ences in social class, education level, and raised DBP
were observed between exposure groups. The propor-
tion of participants using topical beta-blockers with
self-reported glaucoma was predictably high, with
89.9% of users reporting glaucoma. Of the 514 partici-
pants with glaucoma, 353 (68.7%) were not using topi-
cal beta blockers compared with 161 (31.3%) who were.
Table 3 details the results of the Cox proportional
hazards analysis for the complete cohort. Topical beta-
blocker use was not associated with cardiovascular
mortality (hazard ratio, HR, 1.12, 95% CI 0.80–1.56)
when adjusted for age and sex. Table 3 also presents the
maximally adjusted model; no significant association
was found between use of topical beta-blockers and
cardiovascular mortality (HR 0.93, 95% CI 0.67–1.30).
At baseline, 514 participants (2.0%) had glaucoma of
which 229 (44.6%) died during follow-up. Of these 92
participants (17.9%) died of cardiovascular causes.
Overall, 285 participants with glaucoma were alive at the
end of the study. Table 4 shows the results of the Cox
proportional hazards analysis for glaucoma patients
adjusted for age and sex. Comparing participants report-
ing glaucoma and using topical beta-blockers to those
reporting glaucoma not using topical beta-blockers,
there was no association with cardiovascular mortality
when adjusted for age and sex (HR 0.76, 95% CI 0.49–
1.18) or when fully adjusted (HR 0.89, 95% CI 0.56–1.40).
Results from the sensitivity analyses did not indicate sub-
stantial effects to the final model from additional covari-
ables, inclusion of cholesterol or higher levels of beta-
blocker use with follow-up time. Sensitivity analysis to
estimate the impact of incident glaucoma did not indicate
Figure 1. Flowchart of the literature review on the association
between topical beta-blockers and cardiovascular mortality
illustrating the exclusion process of retrieved publications.
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Table 1. Summary of three published studies reporting associations between topical beta-blocker use and cardiovascular mortality.
Author
Study
design Participants Exposure
Exposure
assessment Outcome Outcome assessment Covariables Results
Lee et al.2 Cohort
study
N = 3654,
49–97
years, Blue
Mountains,
Australia
Glaucoma
status,
baseline
medications
Detailed baseline
eye examinations
using Humphrey
30-2 visual field
test for glaucoma.
Face-to-face
interviews for
medication history.
All-cause
mortality
and
cause of
death
Matching participant
demographic data to
the Australian
National Death Index
using a probabilistic
linkage package. Non-
exact matches
examined manually
and corroborated with
information from
family members.
Age, sex,
hypertension,
diabetes, heart
attack, angina,
stroke, cancer,
smoking, alcohol
consumption, oral
beta-blocker use,
myopia, cataract
No association
between all-cause
mortality and
glaucoma. Increased
risk of cardiovascular
mortality in those
with glaucoma in
<75 years cohort and
previously diagnosed
glaucoma (RR 2.78
95% CI 1.20–6.47).
Further stratified
analysis showed
increased risk in
those with
previously diagnosed
glaucoma (RR 1.85,
95% CI 1.12–3.04),
more so in those
using topical timolol
as part of a trend
analysis (RR 2.14,
95% CI 1.18–3.89).
No association of
increased risk of CVD
shown in the 88
baseline users of
timolol vs non-users
(RR 1.47, 95% CI
0.90–2.41).
Muskens
et al.9
Cohort
study
N = 3842,
55+ years,
Rotterdam,
Netherlands
Topical
beta-
blockers
All pharmacies in
region using fully
automated single
network on use,
date and type of
beta-blocker.
Matched to
participants.
All-cause
mortality
and
cause of
death
From municipal
registry, vital status
checked on bi-weekly
basis along with GP
reported deaths. All
deaths checked by
specially trained
personnel. CVD deaths
according to relevant
ICD-10 codes.
Mortality data in
100% of cases.
Certainty of cause in
84% of cases.
Age, sex, smoking,
hypertension,
diabetes, angina
No association
between topical
beta-blocker use and
all-cause mortality
(HR 0.94, 95% CI
0.71–1.25) or
cardiovascular
mortality (HR 1.02,
95% CI 0.56–1.86).
Wu et al.3 Cohort
study
N = 4092,
40–84
years,
Barbados
Glaucoma
status,
baseline
medications
Detailed baseline
eye examination
including
Humphrey
automated
perimetry and
detailed visual field
assessment.
All-cause
mortality
and
cause of
death
Verified from death
certificates held at
Ministry of Health.
Age, sex, diabetes,
hypertension, CVD,
stroke
No association
between OAG and
increased mortality.
In those with OAG at
baseline, those
treated with timolol
had higher
cardiovascular
mortality (RR 1.91,
95% CI 1.04–3.50).
However when
comparing CVD
mortality in timolol
users to all non-
users, no increased
risk of cardiovascular
mortality was
observed (RR 1.58,
95% CI 0.97–2.58).
CI, confidence interval; CVD, cardiovascular disease; GP, general practitioner; HR, hazard ratio; ICD-10, international classification of diseases 10th revision;
OAG, open-angle glaucoma; RR, relative risk.
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a substantial effect from incident glaucoma cases.
Altogether, 52,986 individuals aged over 40 years cur-
rently live in the catchment area of the initial EPIC-
Norfolk recruitment. Using the UK National Eye Health
Epidemiological Model,14 numbers with incident glau-
coma were calculated from this cohort and applied to
the aging EPIC-Norfolk cohort. Non-conservativemodels
predicted a 1.56% incident rate of glaucoma. Applied to
the baseline population excluding those with self-reported
glaucoma, this predicted an additional 392 cases of inci-
dent glaucoma over the study period. Trends in glaucoma
medication prescribing have changed with time, where
prostaglandins are the preferred medication15 and beta-
blocker prescription has dropped by a factor of four.
Applying an exaggerated 25% prevalence of topical beta-
blocker exposure to these incident cases15 would lead to
an additional 98 topical beta-blocker exposures in the
EPIC-Norfolk cohort. Applying an exaggerated death
rate of 50% to those newly diagnosed with glaucoma on
topical beta-blockers, would add an additional 49 deaths.
Assuming 30% died from cardiovascular causes com-
pared to the 20.1% observed in the present study, along
with adjustments in exposure status in baseline users
through application of historic trends in prescribing,15
did not yield significant associations of cardiovascular
mortality (HR 1.30, 95% CI 0.98–1.70, p = 0.06). This
would suggest the findings of this study are robust to
changes in exposure status over time.
A total of three studies,2,3,9 that looked at topical beta-
blockers and cardiovascular mortality were identified from
the systematic literature search. Figure 2 presents results
from the meta-analysis for the effect of topical beta-block-
ers on cardiovascular mortality, regardless of glaucoma
status. Between-study heterogeneity using the I2 statistic
was 1.1% (p = 0.387). Topical beta-blocker use was not
associated with cardiovascular mortality (pooled HR esti-
mate 1.10, 95% CI 0.84–1.36).
Table 2. Comparison of baseline characteristics between exposure
groups in participants in the European Prospective Investigation
into Cancer Norfolk Cohort Study (EPIC-Norfolk, 1993–2013).
Baseline characteristic
No topical
beta-blocker
use (n =
25,460)
Topical
beta-
blocker use
(n = 179)
p-value for
difference
between
exposure
groupsa
Age, mean (SD), years 59.2 (9.3) 66.6 (7.6) <0.001
Sex, % female 54.8 42.2 <0.001
Diabetes, % 2.3 5.6 0.003
Myocardial infarction, % 3.1 10.1 <0.001
Angina, % 5.1 11.7 <0.001
Self-reported
hypertension, %
14.2 25.7 <0.001
Self-reported raised
cholesterol level, %
8.2 14.0 0.004
Stroke, % 1.4 3.4 0.028
Glaucoma, % 1.4 89.9 <0.001
Systolic blood pressure,
mean (SD) mmHg
135.0 (18.4) 141.0 (19.6) <0.001
Diastolic blood pressure,
mean (SD) mmHg
82.5 (11.3) 83.7 (11.8) 0.178
Smoking status, %
current/ever
54.0 61.8 0.038
Social class, % non-
manual
60.0 66.5 0.080
Education level, % higher 52.9 49.7 0.397
aDichotomous covariables; p-value for independence calculated using Chi-
squared test. Continuous variables; p-value for difference calculated from
unpaired Welch’s T-test.
SD, standard deviation. Table 4. Associations between topical beta-blocker use and
cardiovascular mortality in 514 participants with self-reported
glaucoma in the European Prospective Investigation into Cancer
Norfolk Cohort Study (EPIC-Norfolk, 1993–2013).
Hazard Ratio
(95% confidence interval) p-value
Model 1: Cardiovascular
mortality in those with
glaucoma
Topical beta-blocker use 0.757 (0.485–1.180) 0.219
Age, per year 1.203 (1.150–1.257) <0.001
Sex, female 0.598 (0.394–0.907) 0.016
Model 2: Cardiovascular
mortality in those with
glaucoma
Topical beta-blocker use 0.885 (0.557–1.401) 0.605
Age, per year 1.195 (1.140–1.252) <0.001
Sex, female 0.765 (0.484–1.210) 0.252
Diabetes 2.550 (1.376–4.729) 0.003
Myocardial infarction 1.119 (0.519–2.413) 0.775
Angina 1.735 (0.905–3.327) 0.097
Stroke 5.119 (2.316–11.316) <0.001
Hypertension 1.015 (0.608–1.694) 0.956
Social class, non-
manual
0.743 (0.465–1.189) 0.216
Smoking status 1.246 (0.756–2.054) 0.389
Model 1 adjusted for age and sex, model 2 adjusted for age, sex, diabetes,
myocardial infarction, angina, stroke, hypertension, social class, and smok-
ing status, using cox proportional hazards model.
Table 3. Associations between topical beta-blocker use and car-
diovascular mortality in the European Prospective Investigation
into Cancer Norfolk Cohort Study (EPIC-Norfolk, 1993–2013).
Hazard Ratio
(95% confidence interval) p-value
Model 1: Cardiovascular mortalitya
Topical beta-blocker useb 1.116 (0.802–1.553) 0.513
Age, per year 1.190 (1.182–1.198) <0.001
Sex, female 0.491 (0.450–0.535) <0.001
Model 2: Cardiovascular mortalitya
Topical beta-blocker use+ 0.931 (0.668–1.299) 0.677
Age, per year 1.178 (1.170–1.187) <0.001
Sex, female 0.590 (0.537–0.648) <0.001
Diabetes 2.118 (1.783–2.516) <0.001
Myocardial infarction 2.287 (1.968–2.659) <0.001
Angina 1.294 (1.128–1.486) <0.001
Stroke 2.272 (1.869–2.761) <0.001
Systolic hypertension 1.579 (1.432–1.740) <0.001
Social class, non-manual 0.854 (0.782–0.933) <0.001
Smoking status 1.339 (1.216–1.475) <0.001
a6525 deaths (25.4%); 2158 deaths due to CVD.
b179 participants on topical beta-blockers, of whom 82 (45.8%) died; 36
from CVD.
Model 1 adjusted for age and sex (N = 25,639), model 2 adjusted for age,
sex, diabetes, myocardial infarction, angina, stroke, hypertension, social
class, and smoking status, using cox proportional hazards model (N =
24,724 due to missing covariables).
CVD, cardiovascular disease.
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Discussion
In this prospective cohort study of 25,639 participants,
topical beta-blocker use was not associated with
increased cardiovascular mortality. Furthermore, in
the 514 participants within the cohort who had self-
reported glaucoma, we did not detect an association
between the use of topical beta-blockers and a higher
risk of cardiovascular mortality. There was also no
evidence of an association between the use of topical
beta-blockers and cardiovascular mortality. These
results do not support higher cardiovascular mortality
from topical beta-blocker use. However, the current
study is based on self-reported glaucoma, which is a
key limitation.
Results from this EPIC-Norfolk study are in agree-
ment with the Rotterdam Study9 but differ from the
Blue Mountains Eye Study6 and Barbados Eye Studies.3
In the Blue Mountains Eye Study, the association
between topical beta-blockers and cardiovascular mor-
tality was only seen in participants using timolol with
glaucoma, compared to those not using topical timolol
without glaucoma. The effect on cardiovascular mortal-
ity was not shown in baseline users of timolol before
stratification by glaucoma status (relative risk, RR, 1.47,
95% CI 0.90–2.41). In baseline timolol users in the
Barbados Eye Studies, there was also no association
shown between timolol use and cardiovascular mortal-
ity (RR 1.58, 95% CI 0.97–2.58). The association was
only seen when compared within users diagnosed with
open-angle glaucoma. The primary meta-analysis used
these summary statistics in order to compare like with
like and did not show an association between topical
beta-blocker use and cardiovascular mortality.
Subgroup analysis of participants with self-reported
glaucoma in the present study found no association
between exposure to topical beta-blockers and cardio-
vascular mortality (HR 0.89, 95% CI 0.56–1.40).
There is well-established literature on the protec-
tive effects of oral beta-blockers. Multiple randomized
controlled trials and systematic reviews have found
that use of systemic beta-blockers decreases mortality,
improves survival, and is cardio-protective.16–20
However, the majority of these studies have shown
the protective effect only in participants who are post
myocardial infarction or with established cardiovas-
cular disease. These observed benefits may not trans-
late to people with no pre-existing cardiovascular
disease. The main cardiovascular effects of beta-
blockers include reduction of heart rate, myocardial
contractile force, cardiac output and peripheral vaso-
constriction. Unwanted side effects include bradycar-
dia and exacerbation of heart failure in susceptible
patients, and these complications form a potential
mechanism for increased risk of cardiovascular mor-
tality from topical beta-blocker use, although there is
little observed evidence of this beyond case reports.8
Randomized controlled trials have shown that topical
beta-blockers may have an adverse effect on lipid
profiles. A review of timolol, the most common topi-
cal beta-blocker linked to adverse lipid profiles, found
that when given systemically, timolol reduced mortal-
ity after myocardial infarction21 indicating that any
deleterious effects on serum lipids did not attenuate
its protective effect on the heart.
The strengths of this study lie in its study design;
EPIC-Norfolk is a long-term prospective cohort study.
Other strengths include the long period of follow-up,
the number of participants, and the high number of
Figure 2. Forest plot of random effects meta-analysis examining effect of topical beta-blocker use on cardiovascular mortality. ES,
effect size; CI, confidence interval; Blue Mountains, Blue Mountains Eye Study; Rotterdam, Rotterdam Study; Barbados, Barbados Eye
Studies; EPIC-Norfolk, European Prospective Investigation into Cancer Norfolk Cohort Study.
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incident cardiovascular mortality events, enabling high
statistical power. The large number of covariables mea-
sured at baseline allowed for adjustment of multiple
confounders in the analysis and the assessment of the
robustness of the findings across different analytical
variations. A validation study22 has confirmed accuracy
of cardiovascular mortality in EPIC-Norfolk, with 38 of
39 cases confirmed as correct. Last, the linking of out-
come data through the Office for National Statistics
death register allowed for complete ascertainment of
outcome status in this study, regardless of whether the
participant was lost to follow-up. This eliminated attri-
tion bias.
There were several key limitations of the study.
There was limited power within the subgroup analysis
of glaucoma users whose baseline cohort was small (n =
514). This was further reduced after excluding deaths
not from cardiovascular causes (n = 377) and may have
allowed type II error to occur. There may be a degree of
healthy-volunteer bias occurring. This is suggested by
the considerably lower proportion of current and ex-
smokers, and a higher proportion of never smokers
compared to the rest of England. This may also have
contributed to the relatively low proportions of cardio-
vascular deaths in this older population. The study only
assigned participants to the exposed category if topical
beta-blockers were used before or at baseline and no
adjustments were made for changes in exposure status
with time. Additionally, it was not possible to ascertain
compliance of individuals exposed to topical beta-
blockers, who may have filled prescriptions they were
not taking. This may have resulted in an underestimate
of effect. Our methods are in line with the previous
studies examined in the meta-analysis, and allowed for
direct comparisons. We did, however, examine the
impact of incident glaucoma and did not detect a sig-
nificant effect. Publication bias was possible in the
meta-analyses, but the use of a funnel plot was of little
value due to the number of studies identified. It is
plausible that there are smaller studies that have
unpublished non-significant results that would
strengthen the absence of an association between topi-
cal beta-blocker use and cardiovascular mortality and
favor the null hypothesis.
We did not examine the relationship between glau-
coma diagnosis and mortality as it was beyond the
scope of this study. It is possible that topical beta-
blocker use may mask heterogeneous pathophysiologi-
cal processes that underpin both glaucoma and ocular
hypertension. Both conditions are treated with topical
beta-blockers and display different associations with
hypertension and diabetes.23–26 This is particularly rele-
vant to this study as we used self-reported glaucoma,
where participants could report a glaucoma diagnosis
even if they had ocular hypertension. Furthermore, up
to 50% of glaucoma in the community can be
undiagnosed.27,28 These considerations would lead to
a measurement error in exposure ascertainment, and
although likely to contribute to a null finding, the exact
impact is unknown.
In conclusion, no association was observed between
topical beta-blocker use and cardiovascular mortality in
all participants or in participants with self-reported
glaucoma. A meta-analysis with other large popula-
tion-based studies showed no association in the pooled
estimates between topical beta-blockers and cardiovas-
cular mortality, both for all participants and for only
participants with glaucoma. However, further studies
are required that allow for adjustment for changes in
exposure to topical beta-blockers. We have found no
further evidence to suggest that patients using topical
beta-blockers experience excess cardiovascular mortal-
ity, and no indications that current clinical practice
requires revision. Clinicians should continue to exercise
caution when assessing individual glaucoma patients
and their cardiovascular risk prior to commencing
topical beta-blockers.
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